Cushing's syndrome due to ectopic ACTH production by (neuroendocrine) prostate carcinoma

被引:23
作者
Alwani, R. A. [1 ,4 ]
Neggers, S. J. C. M. M. [4 ]
van der Klift, M. [3 ]
Baggen, M. G. A. [3 ]
van Leenders, G. J. L. H. [2 ]
van Aken, M. O. [4 ]
van der Lely, A. J. [4 ]
de Herder, W. W. [4 ]
Feelders, R. A. [4 ]
机构
[1] Erasmus MC, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus MC, Dept Pathol, NL-3000 CA Rotterdam, Netherlands
[3] Ikazia Hosp, Dept Internal Med, Rotterdam, Netherlands
[4] Endocrine Sect, Dept Internal Med, Rotterdam, Netherlands
关键词
Ectopic ACTH; Cushing's syndrome; Neuroendocrine differentiation; Prostate cancer; ACTH staining; CLINICAL-FEATURES; CANCER; DIFFERENTIATION; ADENOCARCINOMA; EXPERIENCE; MANAGEMENT; HORMONE; PLASMA; LUNG;
D O I
10.1007/s11102-008-0100-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ectopic adrenocorticotropin (ACTH) secretion accounts for less than 10% of all causes of endogenous Cushing's syndrome (CS) and is usually associated with neuroendocrine tumors and small cell carcinoma of the lung. We report the case of a 62-year-old man with CS due to ectopic ACTH production by small cell carcinoma of the prostate. He presented with severe hypercortisolism and associated symptoms. Plasma neuron specific enolase (NSE) was grossly elevated. Despite performing a laparoscopic bilateral adrenalectomy, the patient died as a result of sepsis with multi-organ failure. Post-mortem immunohistochemical staining of prostate tumor tissue showed ACTH expression. ACTH staining was also performed in four additional patients with small cell carcinoma of the urinary tract without CS. None of these additional cases showed a positive staining for ACTH. Although a rare cause of ectopic ACTH production, neuroendocrine prostate carcinoma should be considered in male patients with Cushing's syndrome, in particular in those with an occult source of ACTH overproduction.
引用
收藏
页码:280 / 283
页数:4
相关论文
共 31 条
[1]  
Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO
[2]  
2-S
[3]   Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486) [J].
Chu, JW ;
Matthias, DF ;
Belanoff, J ;
Schatzberg, A ;
Hoffman, AR ;
Feldman, D .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (08) :3568-3573
[4]   IMMUNOCYTOCHEMICAL STUDY OF 18 TUMORS CAUSING ECTOPIC CUSHINGS-SYNDROME [J].
COATES, PJ ;
DONIACH, I ;
HOWLETT, TA ;
REES, LH ;
BESSER, GM .
JOURNAL OF CLINICAL PATHOLOGY, 1986, 39 (09) :955-960
[5]   Mechanisms of androgen-refractory prostate cancer. [J].
Debes, JD ;
Tindall, DJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15) :1488-1490
[6]   ECTOPIC CORTICOTROPIN SYNDROME AND SMALL-CELL CARCINOMA OF THE LUNG - CLINICAL-FEATURES, OUTCOME, AND COMPLICATIONS [J].
DELISLE, L ;
BOYER, MJ ;
WARR, D ;
KILLINGER, D ;
PAYNE, D ;
YEOH, JL ;
FELD, R .
ARCHIVES OF INTERNAL MEDICINE, 1993, 153 (06) :746-752
[7]  
DISANTAGNESE PA, 1995, CANCER, V75, P1850, DOI 10.1002/1097-0142(19950401)75:7+<1850::AID-CNCR2820751615>3.0.CO
[8]  
2-4
[9]   Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma [J].
Fixemer, T ;
Remberger, K ;
Bonkhoff, H .
PROSTATE, 2002, 53 (02) :118-123
[10]   CARCINOMA OF THE PROSTATE WITH CUSHINGS-SYNDROME - A CASE-REPORT WITH HISTOCHEMICAL AND CHEMICAL DEMONSTRATION OF IMMUNOREACTIVE CORTICOTROPIN-RELEASING HORMONE IN PLASMA AND TUMORAL TISSUE [J].
FJELLESTADPAULSEN, A ;
ABRAHAMSSON, PA ;
BJARTELL, A ;
GRINO, M ;
GRIMELIUS, L ;
HEDELAND, H ;
FALKMER, S .
ACTA ENDOCRINOLOGICA, 1988, 119 (04) :506-516